Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jan-Feb;47(1):43-55.
doi: 10.1097/NCC.0000000000001151. Epub 2022 Dec 11.

Staying Strong and Healthy During Androgen Deprivation Therapy

Jamie S Myers  1 , Alana Manson, Sandra A Billinger, Jill Hamilton-Reeves, William Parker, Sally L Maliski
Affiliations
Randomized Controlled Trial

Staying Strong and Healthy During Androgen Deprivation Therapy

Jamie S Myers et al. Cancer Nurs. 2024 Jan-Feb.

Abstract

Background: Androgen deprivation therapy (ADT) for prostate cancer is associated with cardiovascular comorbidities and numerous adverse effects decreasing health-related quality of life. Both exercise and dietary interventions have shown promise in reducing ADT-related negative sequelae. However, feasibility for personalized combined exercise/nutrition/education interventions is not well established.

Objective: The purpose of this randomized, controlled, mixed-methods pilot study was to evaluate the feasibility of a nurse-led, telephone-delivered education, exercise, and nutrition intervention, Staying Strong & Healthy, to minimize ADT-related cardiovascular/metabolic risks and symptoms.

Methods: Staying Strong & Healthy involves individually tailored education, exercise (aerobic and resistance), and nutrition intervention delivered over 6 months and was compared with attention control. The primary quantitative outcome measure was change from baseline in low-density lipoprotein. Secondary outcomes included change in lipid levels (total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides), fasting blood glucose, hemoglobin A 1c , health-related quality of life, and diet quality. Assessments were performed at baseline, 6 months, and 12 months.

Results: Feasibility was demonstrated by low attrition rates and high participant satisfaction. No between-group differences were demonstrated in the cardiovascular/metabolic outcomes. Significant within-group improvements were noted for high-density lipoprotein and hemoglobin A 1c in the intervention group.

Conclusion: The study results indicate that participation in a personalized, nurse-delivered exercise, nutrition, and educational intervention is feasible and acceptable to men with prostate cancer receiving ADT.

Implications for practice: Future randomized controlled research powered to detect significant differences is needed to confirm the impact of the Staying Strong & Healthy intervention on reduction of the cardiovascular/metabolic impact of ADT for men with prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure:
Figure:
Consort Diagram
See this image and copyright information in PMC

References

    1. Shevach J, Chaudhuri P, Morgans AK. Adjuvant therapy in high-risk prostate cancer. Clinical advances in hematology & oncology : H&O. 2019;17(1):45–53. - PubMed
    1. Kovtun K, Chen M, Braccioforte M, Moran B, D’Amico A. Race and mortality risk after radiation therapy in men treated with or without androgen supression therapy for favorable-risk prostate cancer. Cancer. 2016;122:3608–3614. - PubMed
    1. Shahinian VB, Kuo Y-f, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–1624. - PubMed
    1. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(1):19–30. - PubMed
    1. Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? Urol Clin North Am. 2017;44(4):611–621. - PMC - PubMed

Publication types